Jeffrey S. Glenn
Stanford University
H-index: 60
North America-United States
Top articles of Jeffrey S. Glenn
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Methods to treat hepatitis delta viral infections | 2024/3/14 | ||
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories | Journal of Hepatology | Devin Razavi-Shearer H Child K Razavi-Shearer A Voeller H Razavi | 2024/2/1 |
PI-kinase inhibitors with anti-infective activity | 2024/1/30 | ||
An updated assessment of hepatitis delta prevalence among adults in Canada: A meta‐analysis | Robert J Wong Grishma Hirode Jordan Feld Steven S Wong Carol Brosgart | 2024/4/15 | |
Programmable Antivirals and Just-in-Time Vaccines: Biosecurity Implications of Viral RNA Secondary Structure Targeting | Health security | Jaspreet Pannu Jeffrey S Glenn | 2023/2/1 |
Treatment of coronavirus infection with interferon lambda | 2023/9/14 | ||
Distinct histological patterns in chronic hepatitis D with nucleos (t) ide analogue therapy | Frontiers in Medicine | Julian Hercun Theo Heller Jeffrey S Glenn David E Kleiner Christopher Koh | 2023/4/6 |
Effectiveness of early-treatment interventions on self-reported long COVID: A multi-arm, multi-stage adaptive platform control trial | Gilmar Reis Lindsay Wilson Dieter Ayers Eduardo Silva Daniela Medeiros | 2023/1/17 | |
HDV RNA Assays: Performance characteristics, clinical utility and challenges | Heiner Wedemeyer Mitchell Leus Thomas R Battersby Jeffrey Glenn Emmanuel Gordien | 2023/8/28 | |
Annual Meeting of the Canadian Association for the Study of the Liver (CASL), the Canadian Network on Hepatitis C (CANHEPC) and the Canadian Association of Hepatology Nurses … | Canadian Liver Journal | M Akl L Li R Baccetto S Phanse Q Zhang | 2023/3/11 |
Pegylated Interferon Lambda for Covid-19. Reply. | N Engl J Med | Gilmar Reis Edward J Mills Jeffrey S Glenn | 2023 |
Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same | 2023/3/9 | ||
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV-and high-HBV/HDV-prevalence countries | Journal of Hepatology | Homie A Razavi Maria Buti Norah A Terrault Stefan Zeuzem Cihan Yurdaydin | 2023/8/1 |
Hepatitis B virus and hepatitis D virus infection in women with or at risk for HIV infection in the United States | Frontiers in Medicine | Ilona Argirion Parag Mahale Ruth M Pfeiffer Ping Liu Adaora A Adimora | 2023/3/2 |
Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or … | J Hepatol | Ohad Etzion Saeed Sadiq Hamid Tarik Asselah George Sebastian Gherlan Adela Turcanu | 2023/6/1 |
Treatment of hepatitis delta virus infection | 2023/10/24 | ||
Early treatment with pegylated interferon lambda for Covid-19 | New England Journal of Medicine | Gilmar Reis Eduardo AS Moreira Silva Daniela C Medeiros Silva Lehana Thabane Vitoria HS Campos | 2023/2/9 |
Treatment of chronic hepatitis D with peginterferon lambda—the phase 2 LIMT-1 clinical trial | Hepatology | Ohad Etzion Saeed Hamid Yoav Lurie Edward J Gane David Yardeni | 2023/6/1 |
1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with … | Annals of Oncology | TU Marron JG Misleh ZA Wainberg J Powderly R Boccia | 2023/10/1 |
P14-Kinase Inhibitors with Anti-Cancer Activity | 2022/3/3 |
